Gut Microbes Emerge as Key Players in Cancer Treatment Success

The human microbiome is emerging as a critical factor in cancer care, with growing evidence that microbes throughout the body significantly influence disease outcomes. This translational science review synthesizes clinical and preclinical data showing how microbes affect every stage of cancer, from initial development to treatment response.

Researchers found that microbes in the gastrointestinal tract and other locations like the respiratory system can influence carcinogenesis, metastasis development, and treatment effectiveness. Importantly, microbes within tumors themselves may determine how well patients respond to therapy.

The gut microbiome appears particularly crucial for immunotherapy success. Studies show that beneficial gut bacteria can be enhanced through interventions like fecal microbiota transplants and high-fiber diets, leading to improved outcomes in cancer immunotherapy patients. Conversely, broad-spectrum antibiotics that disrupt the gut microbiome before treatment are associated with poorer survival rates and increased adverse effects.

These findings suggest that microbiome-targeted therapies could revolutionize cancer treatment. Future interventions focusing on optimizing microbial communities throughout the body may significantly improve patient outcomes and reduce treatment-related complications.